REG-CROSSJECT and BARDA align ZEPIZURE®’s Pediatric development plan with FDA including funding through 2030

English Summary

REG-CROSSJECT and BARDA align ZEPIZURE®’s Pediatric development plan with FDA including funding through 2030

Chinese Summary

REG-CROSSJECT and BARDA align ZEPIZURE®’s Pediatric development plan with FDA including funding through 2030